- Home
- OCGN vs BWAY Comparison
OCGN vs BWAY Comparison
Compare OCGN & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- BWAY
- Stock Information
- Founded
- OCGN 2013
- BWAY 2003
- Country
- OCGN United States
- BWAY Israel
- Employees
- OCGN N/A
- BWAY N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- BWAY Medical/Dental Instruments
- Sector
- OCGN Health Care
- BWAY Health Care
- Exchange
- OCGN Nasdaq
- BWAY Nasdaq
- Market Cap
- OCGN 205.2M
- BWAY 201.1M
- IPO Year
- OCGN N/A
- BWAY 2019
- Fundamental
- Price
- OCGN $0.84
- BWAY $10.22
- Analyst Decision
- OCGN Strong Buy
- BWAY Strong Buy
- Analyst Count
- OCGN 3
- BWAY 2
- Target Price
- OCGN $6.00
- BWAY $14.25
- AVG Volume (30 Days)
- OCGN 4.8M
- BWAY 34.0K
- Earning Date
- OCGN 05-09-2025
- BWAY 05-13-2025
- Dividend Yield
- OCGN N/A
- BWAY N/A
- EPS Growth
- OCGN N/A
- BWAY N/A
- EPS
- OCGN N/A
- BWAY 0.08
- Revenue
- OCGN $4,522,000.00
- BWAY $43,457,000.00
- Revenue This Year
- OCGN N/A
- BWAY $351.53
- Revenue Next Year
- OCGN N/A
- BWAY $21.84
- P/E Ratio
- OCGN N/A
- BWAY $51.42
- Revenue Growth
- OCGN N/A
- BWAY 26.86
- 52 Week Low
- OCGN $0.52
- BWAY $5.67
- 52 Week High
- OCGN $1.98
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- OCGN 56.85
- BWAY 56.53
- Support Level
- OCGN $0.64
- BWAY $10.15
- Resistance Level
- OCGN $0.81
- BWAY $11.06
- Average True Range (ATR)
- OCGN 0.09
- BWAY 0.51
- MACD
- OCGN 0.00
- BWAY 0.00
- Stochastic Oscillator
- OCGN 53.30
- BWAY 54.72
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.